Efficacy of ponatinib in patients with CP-CML, overall, and among patients resistant or intolerant to previous treatment with dasatinib or nilotinib or with the BCR-ABL1^T315I mutation. (B-C) Results are shown in CP-CML patients remaining on study as of the last response assessment. (B-E) The 95% confidence intervals are shown. (A) Response at any time. MR4 is the 4-log molecular response (≤0.01% BCR-ABL1^IS or undetectable disease in cDNA with ≥10 000 ABL1 transcripts); MR^4.5 is the 4.5-log molecular response (≤0.0032% BCR-ABL1^IS or undetectable disease in cDNA with ≥32 000 ABL1 transcripts). MCyR and MMR rates in patients who were resistant to dasatinib or nilotinib were 54% and 41%, respectively. (B) Duration of MCyR. Patients who achieved MCyR by 12 months (n = 148) are shown. Because of a data correction between the original PACE publication and the current report, 148 (55%) rather than 149 (56%) of 267 CP-CML patients achieved MCyR by 12 months. Of 267 CP-CML patients evaluated for efficacy, 148 achieved MCyR, and 21 of these patients lost MCyR, leaving 127 (48%) of 267 CP-CML patients with continuous MCyR as of the last response assessment. *Failed to meet criteria for MCyR in 2 consecutive assessments ≥28 days apart, or discontinued after a single assessment in which the criteria for MCyR were not met. †Kaplan-Meier estimate. (C) Duration of MMR. Patients who achieved MMR at any time are shown. Of 267 CP-CML patients evaluated for efficacy, 108 achieved MMR, and 28 of these patients lost MMR, leaving 80 (30%) of 267 CP-CML patients with continuous MMR as of last response assessment. *Failed to meet criteria for MMR at any single time point after initial response. †Kaplan-Meier estimate. (D) PFS. Progression from CP was defined as death, development of AP or BP, loss of complete hematologic response (in absence of cytogenetic response), loss of MCyR, or increasing white blood cell count without complete hematologic response. (E) OS.